Thursday, October 15, 2026

Marathon Petroleum Secures 300,000 Barrels Daily From Gulf Coast Fractionators as Global NGL Demand Surges

Marathon Petroleum has locked in full output from two Gulf Coast fractionators processing 150,000 barrels per day each, set to operate between 2028-2029. The deal secures feedstock for Marathon's operations while Asian petrochemical expansion drives 3-4% annual ethylene capacity growth through 2030, much of it dependent on U.S. natural gas liquid exports.

ViaNews Editorial Team

February 21, 2026

Source Trace Score1 source document1 with a live linkVerifiability: Basic
Marathon Petroleum Secures 300,000 Barrels Daily From Gulf Coast Fractionators as Global NGL Demand Surges
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Marathon Petroleum has secured all output from two fractionators starting operations on the Gulf Coast between 2028 and 2029, each processing 150,000 barrels per day of natural gas liquids. The combined 300,000-barrel capacity targets growing Asian demand for ethane and propane as petrochemical feedstocks.

Fractionators separate mixed NGLs into ethane, propane, and butane used in plastics manufacturing and fuel blending. Marathon's full offtake agreement provides revenue certainty before construction begins on facilities costing $400-600 million each. Midstream developers typically require contracts covering 70-80% of capacity before greenlighting such projects.

The timing aligns with projected global ethylene capacity growth of 3-4% annually through 2030, concentrated in Asia. U.S. producers hold cost advantages from abundant shale gas, with domestic NGL output reaching 6.5 million barrels per day in 2024. Permian Basin and Appalachian production drove Gulf Coast fractionation capacity expansion since 2015.

These two units will add 10% to the Gulf Coast's existing 3 million barrels per day of fractionation capacity in Texas and Louisiana. The region sits near major gas processing areas and export terminals serving international markets increasingly reliant on U.S. NGL supplies.

Marathon operates a 1.9 million-barrel-per-day refining network and midstream infrastructure through its MPLX partnership. The integrated model lets the company optimize margins across gathering, processing, fractionation, and refining rather than depending solely on refining spreads.

Marathon has not disclosed financial terms or identified facility operators. The commitment signals continued confidence in NGL supply growth despite recent moderation in U.S. drilling activity, banking on sustained Asian petrochemical demand for American exports.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· February 20, 2026
    MPLX LP: Why This Midstream MLP Deserves a Premium Valuation
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com